1. Home
  2. BCG vs SCLX Comparison

BCG vs SCLX Comparison

Compare BCG & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCG
  • SCLX
  • Stock Information
  • Founded
  • BCG 2016
  • SCLX 2011
  • Country
  • BCG United States
  • SCLX United States
  • Employees
  • BCG N/A
  • SCLX N/A
  • Industry
  • BCG
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCG
  • SCLX Health Care
  • Exchange
  • BCG Nasdaq
  • SCLX Nasdaq
  • Market Cap
  • BCG 32.5M
  • SCLX 35.7M
  • IPO Year
  • BCG N/A
  • SCLX N/A
  • Fundamental
  • Price
  • BCG $2.00
  • SCLX $18.18
  • Analyst Decision
  • BCG
  • SCLX Strong Buy
  • Analyst Count
  • BCG 0
  • SCLX 3
  • Target Price
  • BCG N/A
  • SCLX $367.50
  • AVG Volume (30 Days)
  • BCG 12.9K
  • SCLX 324.6K
  • Earning Date
  • BCG 08-13-2025
  • SCLX 08-13-2025
  • Dividend Yield
  • BCG N/A
  • SCLX N/A
  • EPS Growth
  • BCG N/A
  • SCLX N/A
  • EPS
  • BCG N/A
  • SCLX N/A
  • Revenue
  • BCG $173,961,000.00
  • SCLX $44,236,000.00
  • Revenue This Year
  • BCG N/A
  • SCLX $89.26
  • Revenue Next Year
  • BCG N/A
  • SCLX $203.95
  • P/E Ratio
  • BCG N/A
  • SCLX N/A
  • Revenue Growth
  • BCG 7.45
  • SCLX N/A
  • 52 Week Low
  • BCG $1.71
  • SCLX $3.60
  • 52 Week High
  • BCG $6.55
  • SCLX $45.15
  • Technical
  • Relative Strength Index (RSI)
  • BCG 44.95
  • SCLX 62.09
  • Support Level
  • BCG $1.93
  • SCLX $15.61
  • Resistance Level
  • BCG $2.07
  • SCLX $20.41
  • Average True Range (ATR)
  • BCG 0.12
  • SCLX 2.19
  • MACD
  • BCG -0.02
  • SCLX -0.17
  • Stochastic Oscillator
  • BCG 15.70
  • SCLX 58.75

About BCG Binah Capital Group Inc. Common Stock

Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: